Last reviewed · How we verify
Acute Lymphoblastic Leukemia (ALL) in pediatric and adult patients — Treatment Landscape & Competitive Intelligence
1 marketed
0 Phase 3
0 Phase 2
Live · 30-min refresh
Marketed treatment landscape
| Drug | Generic | Sponsor | Class | Target | Line of therapy | First approval |
|---|---|---|---|---|---|---|
| Asparlas | calaspargase | Pfizer | Asparagine-specific Enzyme [EPC] | L-asparagine | 2018-01-01 |
Phase 3 pipeline
Phase 2 pipeline
Recent regulatory actions (last 90 days)
Upcoming PDUFA dates (next 180 days)
Sponsor landscape
- Pfizer · 1 drug in Acute Lymphoblastic Leukemia (ALL) in pediatric and adult patients
Subscribe to ongoing alerts
Every new regulatory action, PDUFA date, or trial completion in Acute Lymphoblastic Leukemia (ALL) in pediatric and adult patients:
- Acute Lymphoblastic Leukemia (ALL) in pediatric and adult patients treatment updates — RSS
- Acute Lymphoblastic Leukemia (ALL) in pediatric and adult patients treatment updates — Atom
- Acute Lymphoblastic Leukemia (ALL) in pediatric and adult patients treatment updates — JSON
Cite this brief
Drug Landscape (2026). Acute Lymphoblastic Leukemia (ALL) in pediatric and adult patients — Treatment Landscape & Competitive Intelligence Brief. https://druglandscape.com/ci/disease/acute-lymphoblastic-leukemia-all-in-pediatric-and-adult-patients. Accessed 2026-06-10.
Related
- Acute Lymphoblastic Leukemia (ALL) in pediatric and adult patients full disease profile — treatment pathway, diagnostics, guidelines
- Browse all CI briefs
- Build a custom feed
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing